Abstract:Background: Cryptococcus neoformans infections occur in immunocompromised patients, especially those with HIV infection, chemoradiotherapy after cancer, and organ transplantation. Infection can cause pneumonia and meningoencephalitis in severe cases with a high mortality rate if not treated. Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of fluconazole resistance has increased significantly due to long-term use. Minocycline is a derivative of tetracycline that exerts its antibacterial effect through inhibition of bacterial protein synthesis. It is also able to pass the blood-brain barrier to act on the central nervous system. The present study investigates the effects of minocycline in combination with antifungals in treating C. neoformans. Objective: To determine in vitro interactions of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole and amphotericin B against C. neoformans. Methods: The minimum inhibitory concentrations (MIC) of the antifungals were determined by the CLSI Clinical and Laboratory Standards Institute M27-A3 microdilution method. The in vitro synergistic effects of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole, and amphotericin B on C. neoformans were detected by the broth microdilution checkerboard technique and disk diffusion testing. Results and conclusion: The working concentration ranges were 0.125-4 µg/mL for itraconazole, 0.03-0.125 µg/ml for voriconazole, 0.03-1 µg/ml for posaconazole, 0.25-16 µg/ml for fluconazole, and 0.125-2 µg/ml for amphotericin B. The synergistic rates of minocycline combinations against C. neoformans were 55% with itraconazole, 10% with voriconazole, 85% with posaconazole, 20% with fluconazole, and 70% with amphotericin B. The effective MIC value of minocycline in the synergistic combination decreased to 2-32 µg/ml, while the MIC of itraconazole decreased to 0.03-0.125 µg/ml, voriconazole 0.03-0.125 µg/ml, posaconazole 0.03-0.125 µg/ml, 0.125-4 µg/ml fluconazole, and 0.06-0.50 µg/ml amphotericin B. The disk diffusion assay showed that the plates containing minocycline and antifungal drugs produced inhibition zones with diameters larger than the single drug plates. Minocycline showed no antagonistic effect in the combinations. In conclusion, the combination of minocycline and azoles or amphotericin B has synergistic effects against C. neoformans in vitro.

In Vitro Synergistic Antifungal Activities of Caspofungin in Combination with Fluconazole or Voriconazole Against Candida Species Determined by the Etest Method

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

Antifungal activity of combination of caspofungin and voriconazole, itraconazole or amphotericin B against clinical strains of Scedosporium apiospermum in vitro

Resistance Reversal Induced by a Combination of Fluconazole and Tacrolimus (FK506) in Candida Glabrata.

Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis

Synergistic Antifungal Effect of Glabridin and Fluconazole.

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Rapamycin and caspofungin show synergistic antifungal effects in caspofungin-susceptible and caspofungin-resistant Candida strains in vitro

Synergism of Caspofungin and Terbinafine Against Clinical and Environmental Isolates of Cryptococcus Neoformans

In vitro activities of six antifungal agents and their combinations against Chaetomium spp.

The Effect of Ginkgolide B Combined with Fluconazole Against Drug-Resistant Candida Albicans Based on Common Resistance Mechanisms

In Vitro Combined Activity of Amphotericin B, Caspofungin and Voriconazole Against Clinical Isolates of Trichosporon Asahii

Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans

In Vitro Interaction Between Azoles and Cyclosporin A Against Clinical Isolates of Candida Albicans Determined by the Chequerboard Method and Time-Kill Curves

In Vitro Interactions Between Tacrolimus and Azoles Against Candida Albicans Determined by Different Methods.

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans

In vitro interactions of itraconazole with caspofungin or terbinafine against Sporothrix globosa

In Vitro Synergism of Fluconazole and Baicalein Against Clinical Isolates of Candida Albicans Resistant to Fluconazole.

Synergistic Activity of Azoles with Amiodarone Against Clinically Resistant Candida Albicans Tested by Chequerboard and Time-Kill Methods.

In Vitro Susceptibility Testing of Aspergillus Spp. Against Voriconazole, Itraconazole, Posaconazole, Amphotericin B and Caspofungin